Sangamo BioSciences Inc (SGMO)

5.77
NASDAQ : Health Care
Prev Close 5.85
Day Low/High 5.75 / 5.98
52 Wk Low/High 4.63 / 9.91
Avg Volume 818.20K
Exchange NASDAQ
Shares Outstanding 70.49M
Market Cap 412.38M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS II

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS II

Company Advances Third In Vivo Protein Replacement Platform™ (IVPRP) Program into Clinical Development

Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor

Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor

Leadership Transition Underlines Evolution from a Platform Company to a Therapeutic Product Company

Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic® Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy

Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic® Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy

New Histologic Data Demonstrate Disease Correction in Tissues after ZFP Therapeutic Treatment in Mouse Model of MPS I

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Today's Weak On High Volume Stock: Sangamo BioSciences (SGMO)

Today's Weak On High Volume Stock: Sangamo BioSciences (SGMO)

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a weak on high relative volume candidate

Commit To Buy Sangamo BioSciences At $5, Earn 23% Using Options

Commit To Buy Sangamo BioSciences At $5, Earn 23% Using Options

Investors considering a purchase of Sangamo BioSciences Inc shares, but tentative about paying the going market price of $6.91/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.15.

These 5 Biotech Stocks Under $10 Are About to Break Out

These 5 Biotech Stocks Under $10 Are About to Break Out

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Sangamo BioSciences (SGMO) Flagged As Strong On High Volume

Sangamo BioSciences (SGMO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a strong on high relative volume candidate

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform Programs For MPS I And MPS II At The 12th Annual WORLDSymposium™ Meeting

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform Programs For MPS I And MPS II At The 12th Annual WORLDSymposium™ Meeting

IVPRP Approach Permits Therapeutic Enzymes for Lysosomal Storage Disorders to Cross the Blood Brain Barrier Improving Cognitive Symptoms of Disease

Sangamo BioSciences Presents Phase 2 Immunological Data From SB-728-T ZFP Therapeutic® HIV Program At CROI 2016

Sangamo BioSciences Presents Phase 2 Immunological Data From SB-728-T ZFP Therapeutic® HIV Program At CROI 2016

Subjects from SB-728-1101 Cohort 3* Remain Off Antiretroviral Therapy for Over a Year

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Program is the Second of the Company's In Vivo Protein Replacement Platform™ Programs to Enter Clinical Development

Sangamo BioSciences Becomes Oversold (SGMO)

Sangamo BioSciences Becomes Oversold (SGMO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Strong On High Volume: Sangamo BioSciences (SGMO)

Strong On High Volume: Sangamo BioSciences (SGMO)

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a strong on high relative volume candidate

Oversold Conditions For Sangamo BioSciences (SGMO)

Oversold Conditions For Sangamo BioSciences (SGMO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Sangamo BioSciences Highlights 2016 Catalysts At The 34th Annual J.P. Morgan Healthcare Conference

Sangamo BioSciences Highlights 2016 Catalysts At The 34th Annual J.P. Morgan Healthcare Conference

Sangamo Names Fabry Disease as Fourth Lysosomal Storage Disorder Target

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Preliminary Data Suggest Adenoviral Delivery Method Superior for Immune Stimulation and Control of Viral Load in the Absence of Antiretroviral Therapy (ART)

Sangamo BioSciences (SGMO) Is Strong On High Volume Today

Sangamo BioSciences (SGMO) Is Strong On High Volume Today

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a strong on high relative volume candidate